A Prospective Randomized Pilot Study of Site-specific Atlas Incorporation into Target Volume Delineation Instructions in the Cooperative Group Setting: Preliminary Results from a Southwest Oncology Group Pilot using Big Brother

2009 ◽  
Vol 75 (3) ◽  
pp. S136-S137 ◽  
Author(s):  
C.D. Fuller ◽  
J. Duppen ◽  
C.R.N. Rasch ◽  
L. Kachnic ◽  
S.J. Wang ◽  
...  
Keyword(s):  
Pilot Study ◽  
Target Volume ◽  
Cooperative Group ◽  
Oncology Group ◽  
Group Setting ◽  
Site Specific ◽  
Target Volume Delineation ◽  
Southwest Oncology Group ◽  
Big Brother ◽  
Volume Delineation

scholarly journals Integrating respiratory-gated PET-based target volume delineation in liver SBRT planning, a pilot study

2014 ◽  
Vol 9 (1) ◽  
Author(s):  
Olivier Riou ◽  
Benjamin Serrano ◽  
David Azria ◽  
Benoit Paulmier ◽  
Remy Villeneuve ◽  
...  
Keyword(s):  
Pilot Study ◽  
Target Volume ◽  
Target Volume Delineation ◽  
Volume Delineation ◽  
Gated Pet ◽  
Liver Sbrt

Observer variation in target volume delineation of lung cancer related to radiation oncologist–computer interaction: A ‘Big Brother’ evaluation

2005 ◽  
Vol 77 (2) ◽  
pp. 182-190 ◽  
Author(s):  
Roel J.H.M. Steenbakkers ◽  
Joop C. Duppen ◽  
Isabelle Fitton ◽  
Kirsten E.I. Deurloo ◽  
Lambert Zijp ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Target Volume ◽  
Observer Variation ◽  
Radiation Oncologist ◽  
Target Volume Delineation ◽  
Big Brother ◽  
Volume Delineation ◽  
Computer Interaction

Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.

1990 ◽  
Vol 8 (12) ◽  
pp. 1951-1958 ◽  
Author(s):  
T P Miller ◽  
S Dahlberg ◽  
J K Weick ◽  
J C Files ◽  
H J Eyre ◽  
...  
Keyword(s):  
Cell Lymphoma ◽  
Clinical Stage ◽  
Large Cell ◽  
Cooperative Group ◽  
Oncology Group ◽  
Diffuse Large Cell Lymphoma ◽  
Group Setting ◽  
Southwest Oncology Group ◽  
Large Cell Lymphoma ◽  
Hodgkin's Lymphomas

Chemotherapy using cyclophosphamide, doxorubicin, etoposide, cytarabine, bleomycin, vincristine, methotrexate with leucovorin, and prednisone (ProMACE-CytoBOM) for patients with intermediate- and high-grade non-Hodgkin's lymphomas was tested by the Southwest Oncology Group (SWOG) to confirm the activity of the regimen and to test the feasibility and safety of administering third-generation drug regimens in a cooperative group setting. On day 1, cyclophosphamide, doxorubicin, and etoposide were administered, followed by cytarabine, bleomycin, vincristine and methotrexate with leucovorin given on day 8. There were 51 complete remissions (CRs) among 78 previously untreated patients (65%) having clinical stage II-IV disease. The median length of follow-up is 37.9 months with 57% of patients alive at 3 years and 50% of CR patients free of disease at 3 years. Patients with diffuse large-cell lymphoma have the best survival (63% at 3 years) and relapse-free survival (RFS; 68% at 3 years with no relapses seen after 14 months). Administration of ProMACE-CytoBOM is feasible and safe in a cooperative group setting with 84% of 537 courses of treatment given exactly according to schedule and fatal toxicities seen in five patients (6%). ProMACE-CytaBOM may represent improved treatment for diffuse large-cell lymphoma, but the modest differences compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) indicate the need for a prospective randomized comparative trial.

scholarly journals FIELDRT: an open-source platform for the assessment of target volume delineation in radiation therapy

2021 ◽  
pp. 20210356
Author(s):  
Concetta Piazzese ◽  
Elin Evans ◽  
Betsan Thomas ◽  
John Staffurth ◽  
Sarah Gwynne ◽  
...  
Keyword(s):  
Professional Development ◽  
At Risk ◽  
Open Source ◽  
Organs At Risk ◽  
Target Volume ◽  
Individual Performance ◽  
Continuous Professional Development ◽  
Site Specific ◽  
Target Volume Delineation ◽  
Volume Delineation

Objectives: Target volume delineation (TVD) has been identified as a weakness in the accuracy of radiotherapy, both within and outside of clinical trials due to the intra/inter observer variations affecting the TVD quality. Sources of variations such as poor compliance or protocol violation may have adverse effect on treatment outcomes. In this paper, we present and describe the FIELDRT software developed for the ARENA project to improve the quality of TVD through qualitative and quantitative feedbacks and individual and personalized summary of trainee”s performance. Methods: For each site-specific clinical case included in the FIELDRT software, reference volumes, minimum and maximum “acceptable” volumes and organ at risk were derived by outlines of consultants and senior trainees. The software components currently developed include: (a) user-friendly importing interface (b) analysis toolbox to compute quantitative and qualitative (c) visualizer and (d) structured report generator for personalized feedback. The FIELDRT software was validated by comparing the performance of 63 trainees and by measuring performance over time. In addition, a trainee evaluation day was held in 2019 to collect feedback on FIELDRT. Results: Results show the trainees’ improvement when re-outlining a case after reviewing the feedback generated from the FIELDRT software. Comments and feedback received after evaluation day were positive and confirmed that FIELDRT can be a useful application for training purposes. Conclusions: We presented a new open-source software to support education in TVD and ongoing continuous professional development for clinical oncology trainees and consultants. ARENA in combination with FIELDRT implements site-specific modules with reference target and organs at risk volumes and automatically evaluates individual performance using several quantitative and qualitative feedbacks. Pilot results suggests this software could be used as an education tool to reduce variation in TVD so to guarantee high quality in radiotherapy. Advances in knowledge: FIELDRT is a new easy and free to use software aiming at supporting education in target volume delineation and ongoing continuous professional development. The software provides quantitative/qualitative feedback and an exportable report with an individual and personalized summary of trainee’s performance.

Technical illustration of Volumetric arc conformal radiotherapy planning in a case of paratesticular sarcoma

2021 ◽  
pp. 1-6
Author(s):  
Anil Gupta ◽  
Rambha Pandey ◽  
Seema Sharma ◽  
Vivek Ghosh ◽  
Ekta Dhamija ◽  
...  
Keyword(s):  
Organs At Risk ◽  
Target Volume ◽  
Radiotherapy Planning ◽  
Current Evidence ◽  
Lower Grade ◽  
Malignant Tumours ◽  
Target Volume Delineation ◽  
Volume Delineation ◽  
Delivery Technique ◽  
Technical Illustration

Abstract Introduction: Paratesticular sarcoma are extremely rare malignant tumours. Unlike other sites, they tend to be lower grade and have higher propensity of lymphatic spread. They tend to fail locally and occasionally in the regional lymph nodes. In the absence of target volume delineation guidelines and technical illustration of conformal planning, we have made an attempt to illustrate conformal planning methodology and define target volume based on current evidence in a case of paratesticular sarcoma. Methods: We are presenting a case of 62-year-old male who presented with 15-cm scrotal swelling and underwent high inguinal orchidectomy with ligation of spermatic cord. Histopathology presented a well-differentiated leiomyosarcoma of epididymis. Post-operative radiotherapy target volume included the tumour bed, ipsilateral inguinal nodes and lower pelvic nodes as the clinical target volume. Conclusion: Adjuvant radiotherapy using advanced delivery technique such as volumetric arc technique can provide good dose distribution with good sparing of organs at risk. The downside of conformal radiation delivery is that it is a resource-intensive and has no established target volume delineation guidelines.

Sign in / Sign up

Export Citation Format

Share Document